AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

CONVENIENCE TRANSLATION INTO ENGLISH OF
CONSOLIDATED FINANCIAL STATEMENTS AT 30 SEPTEMBER 2026

(ORIGINALLY ISSUED IN TURKISH)

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 SEPTEMBER 2026

(Amounts expressed in thousands of Turkish Lira ('TRY') based on the purchasing power of the Turkish Lira ("TL") as of 30 September 2026, unless otherwise indicated.)

	30 September 2026 USD (*)	30 September 2026 TL	31 December 2025 TL
Current assets	**559.318**	**27.357.880**	**25.736.034**
Cash and cash equivalents	143.809	7.034.135	6.163.136
Financial investments	-	-	349.999
Trade receivables			
- Due from third parties	109.186	5.340.630	4.083.669
- Due from related parties	77.267	3.779.300	3.298.494
Other receivables			
- Due from third parties	1.141	55.793	36.262
Derivative financial assets	973	47.578	25.684
Inventories	175.333	8.576.102	9.498.631
Prepaid expenses	12.528	612.794	316.970
Current tax assets	1.163	56.868	105.175
Other current assets	37.918	1.854.680	1.858.014
Non-current assets	**1.127.754**	**55.161.976**	**59.388.265**
Financial investments	1.273	62.256	56.584
Investment properties	19.983	977.443	994.497
Property, plant and equipment	902.698	44.153.776	47.522.925
Right of use assets	10.591	518.059	316.247
Intangible assets and goodwill			
- Goodwill	60.633	2.965.748	2.965.748
- Other intangible assets	125.794	6.152.959	6.981.695
Prepaid expenses	6.782	331.735	550.569
Total assets	**1.687.072**	**82.519.856**	**85.124.299**

(*) US Dollar ("USD") amounts presented above have been translated from Turkish Lira ("TL") for convenience purposes only, at the official TL bid rate announced by the Central Bank of the Republic of Turkey ("CBRT") at 30 September 2026 and therefore do not form part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 SEPTEMBER 2026

(Amounts expressed in thousands of Turkish Lira ('TRY') based on the purchasing power of the Turkish Lira ("TL") as of 30 September 2026, unless otherwise indicated.)

	30 September 2026 USD (*)	30 September 2026 TL	31 December 2025 TL
Current liabilities	**585.924**	**28.659.402**	**30.360.115**
Current borrowings			
- Current borrowings from related parties	108.220	5.293.388	3.661.780
- Current borrowing to other parties	183.008	8.951.471	15.946.690
Current portion of non-current borrowings			
- Bank loans	109.379	5.350.066	3.335.242
- Lease liabilities	867	42.430	19.647
Trade payables			
- Due to third parties	146.136	7.147.968	5.687.668
- Due to related parties	15.623	764.181	565.163
Payables related to employee benefits	2.719	133.008	106.924
Other payables			
- Other payables to third parties	2.221	108.564	115.825
Deferred income other than contract liabilities	11.729	573.725	588.591
Current income tax liabilities	-	-	20.310
Current provisions			
- Current provisions for employee benefits	6.020	294.481	312.126
- Other current provisions	2	120	149
Non-current liabilities	**285.651**	**13.971.939**	**12.946.627**
Long-term borrowings			
- Bank loans	203.373	9.947.614	9.413.239
- Lease liabilities	7.206	352.459	173.772
Non-current provisions			
- Non-current provisions for employee benefits	8.389	410.352	422.604
Other non-current liabilities	2.861	139.769	231.141
Deferred tax liabilities	63.822	3.121.745	2.705.871
Total liabilities	**871.575**	**42.631.341**	**43.306.742**
EQUITY	**815.497**	**39.888.515**	**41.817.557**
Attributable to equity holders of the parent	**794.061**	**38.840.032**	**40.681.806**
Paid-in capital	79.427	3.885.000	3.885.000
Inflation adjustments on capital	215.301	10.531.045	10.531.045
Effects of business combinations under common control	1.638	80.130	80.130
Other accumulated comprehensive income/(loss) that will not be reclassified in profit and loss			
- Gains/(losses) on remeasurements of defined benefit plans	(3.715)	(181.702)	(215.227)
Other revaluation and measurement gains/losses	88	4.321	3.843
Other comprehensive income/(loss) that will be reclassified in profit and loss			
- Currency translation differences	(36.677)	(1.793.962)	68.103
Restricted reserves	119.798	5.859.690	5.571.109
Retained earnings	366.437	17.923.570	15.764.704
Net profit for the period	51.764	2.531.940	4.993.099
Non-controlling interests	**21.436**	**1.048.483**	**1.135.751**
Total liabilities and equity	**1.687.072**	**82.519.856**	**85.124.299**

(*) USD amounts presented above have been translated from Turkish Lira ("TL") for convenience purposes only, at the official TL bid rate announced by the CBRT at 30 September 2026 and therefore do not form part of these consolidated financial statements.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH

AKSA AKRİLİK KİMYA SANAYİİ A.Ş.

FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 SEPTEMBER 2026

(Amounts expressed in thousands of Turkish Lira ('TRY') based on the purchasing power of the Turkish Lira ("TL") as of 30 September 2026, unless otherwise indicated.)

Profit or loss	**2026 USD (*)**	**2026 TL**	**2025 TL**
Revenue	781.227	35.604.756	30.404.191
Cost of sales (-)	(676.089)	(30.813.034)	(26.577.525)
Gross profit	**105.138**	**4.791.722**	**3.826.666**
General administrative expenses (-)	(31.118)	(1.418.226)	(1.228.746)
Marketing expenses (-)	(30.812)	(1.404.277)	(1.190.486)
Research and development expenses (-)	(5.869)	(267.486)	(173.950)
Other income from operating activities	31.669	1.443.322	4.051.164
Other expense from operating activities (-)	(27.687)	(1.261.860)	(1.338.662)
Profit from operating activities	**41.321**	**1.883.195**	**3.945.986**
Investment activity Income	1.688	76.946	2.352.892
Share of profit/(loss) of investment accounted for using equity method	-	-	(52.554)
Profit before financing income	**43.009**	**1.960.141**	**6.246.324**
Finance income	40.106	1.827.827	1.996.952
Finance expense (-)	(95.615)	(4.357.704)	(6.271.772)
Monetary gain/(loss), net	77.938	3.552.050	948.153
Profit/(loss) from continuing operations, before tax	**65.438**	**2.982.314**	**2.919.657**
Tax (expense)/income, continuing operations			
- Current period tax expense (-)	(1.737)	(79.152)	(137.962)
- Deferred tax expense	(10.060)	(458.490)	522.466
Profit from continuing operations	**53.641**	**2.444.672**	**3.304.161**
Attributable to:			
Owners of parent	55.555	2.531.940	3.349.095
Non-controlling interests	(1.915)	(87.268)	(44.934)
Basic earnings per share from continuing operations (Kr)	0,63	0,63	0,86
Other comprehensive income/(loss):			
Other comprehensive income that will not be reclassified to profit or loss			
Gains /(losses) on remeasurements of defined benefit plans	931	42.437	34.174
Gains/(losses) on remeasurements of defined benefit plans of associates and joint ventures accounted for using equity method	-	-	(3.921)
Taxes relating to components of other comprehensive income that will not be reclassified to profit or loss	(196)	(8.912)	(8.202)
Other revaluation increases	10	478	437
Other comprehensive income that will be reclassified to profit or loss			
Other comprehensive income / (loss) related with cash flow hedges	-	-	2.143.667
Currency translation differences	(40.857)	(1.862.065)	74.977
Taxes relating to components of other comprehensive income that will be reclassified to profit or loss	-	-	(514.480)
Total comprehensive income	**13.529**	**616.610**	**5.030.813**
Attributable to:			
Owners of parent	15.444	703.878	5.075.747
Non-controlling interests	(1.915)	(87.268)	(44.934)
	13.529	**616.610**	**5.030.813**

(*) USD amounts presented above have been translated from Turkish Lira ("TL") for convenience purposes only, at the USD average CBRT bid rates for the period ended 30 September 2026 and therefore do not form part of these consolidated financial statements.